OmicSyn is an AI-driven bio healthcare company focused on clinical medicine and multi-omics diagnostics and therapeutics. By integrating real-world clinical data with advanced AI technologies, we create innovative solutions that improve precision medicine, clinical research, and patient care.
Through collaboration with hospitals, researchers, and industry partners, OmicSyn aims to advance more predictive, personalized, and data-driven healthcare for a healthier future.
Review Our History
Background of company establishment and key R&D activities
Established the Korea Leukemia Bank supported by
Korea National Research Foundation(KRF)
southIndicated as a representative molecular research lab by
Novartis pharma
southEstablished an online database service system
for the Asia Leukemia Registry Database
southInitiated a research on AI-based clinical management of
leukemia patients
southEstablished OmicSyn Co., Ltd.
southPatent Granted for AI Clinical Decision Support
Selected for National R&D Program by MOTIE
southDevelopment of HemaCDS, Bnote app as a H-Platform
southDevelopment of Dnote app
Selected for Multi-Ministerial Medical R&D Program
